Arshid Yousefi Avarvand (Arshid Yousefi-Avarvand, Arshid Y Avarvand)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Pseudomonas Aeruginosa

Multidrug Resistant

Cervical Cancer Screening

Top Venues

Health science reports

Probiotics and antimicrobial proteins

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Sousan Akrami, Alireza Ekrami, Arshid Yousefi Avarvand
Biofilm generation and antibiotic resistant profile of extensive and multidrug resistant Pseudomonas aeruginosa from burn patients in Ahvaz: A cross-sectional study. Health science reports 7 (6) (2024)
Sousan Akrami, Alireza Ekrami, Fatemeh Jahangirimehr, Arshid Yousefi Avarvand
High prevalence of multidrug-resistant Pseudomonas aeruginosa carrying integron and exoA, exoS , and exoU genes isolated from burn patients in Ahvaz, southwest Iran: A retrospective study. Health science reports 7 (6) (2024)
Sousan Akrami, Alireza Ekrami, Arshid Yousefi Avarvand
Biofilm generation and antibiotic resistant profile of extensive and multidrug resistant Pseudomonas aeruginosa from burn patients in Ahvaz: A cross-sectional study. Health science reports 7 (6) (2024)
Sousan Akrami, Alireza Ekrami, Fatemeh Jahangirimehr, Arshid Yousefi Avarvand
High prevalence of multidrug-resistant Pseudomonas aeruginosa carrying integron and exoA, exoS , and exoU genes isolated from burn patients in Ahvaz, southwest Iran: A retrospective study. Health science reports 7 (6) (2024)
Hedayat Hosseini, Aamin Abbasi, Sahar Sabahi, Sousan Akrami, Arshid Yousefi Avarvand
Assessing the Potential Biological Activities of Postbiotics Derived from Saccharomyces cerevisiae: An In Vitro Study. Probiotics and antimicrobial proteins (2023)
Daryush Purrahman, Arshid Yousefi Avarvand, Agnieszka Paradowska-Gorycka, Najmaldin Saki, Hossein Karimpourian, Hossein Jodat, Mohammad-Reza Mahmoudian-Sani
Association of human papillomavirus with breast cancer: a new perspective on an old debate. Future oncology (London, England) 18 (22) (2022)